Ruthenium -, cis

Benzoylthio)triphenylstannane, Sn-00402 58073-96-4 Tetracarbonylbis(trimethylstannyl)ruthenium cis-form, in Sn-00204... 

Catalytic hydrogenation is mostly used to convert C—C triple bonds into C C double bonds and alkenes into alkanes or to replace allylic or benzylic hetero atoms by hydrogen (H. Kropf, 1980). Simple theory postulates cis- or syn-addition of hydrogen to the C—C triple or double bond with heterogeneous (R. L. Augustine, 1965, 1968, 1976 P. N. Rylander, 1979) and homogeneous (A. J. Birch, 1976) catalysts. Sulfur functions can be removed with reducing metals, e. g. with Raney nickel (G. R. Pettit, 1962 A). Heteroaromatic systems may be reduced with the aid of ruthenium on carbon. 

The hydrogenation of ring A aromatic steroids over ruthenium occurs, almost invariably, from the a side and all substituents on the original aromatic ring are cis in the resulting cyclohexane. Estrone (62) is hydrogenated over ruthenium to 5a,10a-estrane-3/3,17j6-diol (63) in 85-90% yield. 

An example of a stereoselective hydrogenation in ionic liquids was recently successfully demonstrated by Drie en-H6lscher et al. On the basis of investigations into the biphasic water/n-heptane system [51], the ruthenium-catalyzed hydrogenation of sorbic acid to cis-3-hexenoic acid in the [BMIM][PFg]/MTBE system was studied [52], as shown in Scheme 5.2-8. 

In contrast to ruthenium, osmium exists in alkaline solution as 0s04(0H)2, believed to be cis and isolable as crystalline salts ... 

Osmium forms a 6-coordinate acetylacetonate, Os(acac)3, isomorphous with the ruthenium analogue unlike ruthenium, however, the osmium(IV) complexes Os(acac)2X2 (X = Cl, Br, I) can be made (cis- and frans-isomers exist) from OsXg- and Hacac, as can Os(acac)X [176]. 

To a solution of 4-t-butylcyclohexanone (lmmol), tris(triphenylphos-phine)ruthenium(n) chloride (0.05 mmol) and silver trifluoroacetate (0.05 mmol) in toluene (5 ml) was added triethylsilane (1.5 mmol). The mixture was heated under reflux for 20 h, and concentrated under reduced pressure. The residue was diluted with hexane (3 ml), filtered and distilled to give a mixture of triethylsilyl ethers (0.96mmol, 96%), b.p. 70°CI 0.1 mmHg. G.l.c. analysis shows an axial (cis) equatorial (trans) ratio of 5 95—a result comparable to the best LAH results. 

Ruthenium hydride complexes, e.g., the dimer 34, have been used by Hofmann et al. for the preparation of ruthenium carbene complexes [19]. Reaction of 34 with two equivalents of propargyl chloride 35 gives carbene complex 36 with a chelating diphosphane ligand (Eq. 3). Complex 36 is a remarkable example because its phosphine ligands are, in contrast to the other ruthenium carbene complexes described so far, arranged in a fixed cis stereochemistry. Although 36 was found to be less active than conventional metathesis catalysts, it catalyzes the ROMP of norbornene or cyclopentene. 

The use of stoichiometric ruthenium-NHC complexes generated in situ from [Ruljd-COCKp-cymene)], an imidazohnm salt [4] or an imidizol(idin)ium-2-carboxylate [4] has been applied in the cyclopropanation of styrene 5 with ethyl diazoacetate (EDA) 6 (Scheme 5.2). No base was necessary when imidazolium-2 carboxylate were employed. The diastereoselectivity was low and the cis/trans ratio was around 50/50 (Table 5.1). Although the diastereoselectivity was moderate, the reaction was highly chemoselectivity as possible side reactions (homologation, dimerisation and metathesis) were totally or partially suppressed. 

PUSRIE PUSRUQ REBZON ROHXAN 1,4,7,10,13,16-Hexathiacyclooctadecane iodine 1,4,7,10,13,16,19,22-Octathiacyclotetracosane iodine l,2,4,5-Tetrakis(isopropylthio)benzene tris(diiodine) cis-Bis(N,N-diethyldithiocarbamato)-dicarbonyl-ruthenium(II) iodine... 

H-NMR studies of oligocarbene Ru(II) complexes indicate a substantial barrier to rotation about the metal-carbene carbon and nitrogen-R bonds. This restricted rotation is thought to arise as a consequence of intramolecular non-bonding cis interactions of the carbene nitrogen-R substituents, and not because of any significant double bond character in ruthenium-carbene carbon (76). 

Intermolecular cyclopropanation of olefins poses two stereochemical problems enantioface selection and diastereoselection (trans-cis selection). In general, for stereochemical reasons, the formation of /ra ,v-cyclopropane is kinetically more favored than that of cis-cyclopropane, and the asymmetric cyclopropanation so far developed is mostly /ram-selective, except for a few examples. Copper, rhodium, ruthenium, and cobalt complexes have mainly been used as the catalysts for asymmetric intermolecular cyclopropanation. 

Acid-base Equilibria of cis-Dithiocyanato-Ws(2,2-bipyridine-4,4-dicarboxylate) Ruthenium(II)... 

Scheme 3 shows the details of the synthetic strategy adopted for the preparation of heteroleptic cis- and trans-complexes. Reaction of dichloro(p-cymene)ruthenium(II) dimer in ethanol solution at reflux temperature with 4,4,-dicarboxy-2.2 -bipyridine (L) resulted the pure mononuclear complex [Ru(cymene)ClL]Cl. In this step, the coordination of substituted bipyridine ligand to the ruthenium center takes place with cleavage of the doubly chloride-bridged structure of the dimeric starting material. The presence of three pyridine proton environments in the NMR spectrum is consistent with the symmetry seen in the solid-state crystal structure (Figure 24). 

In the iron, ruthenium, osmium, cobalt, and rhodium complexes the xanthato ligands are isobidentate chelating. Selected examples are zra s-Ru(S2COEt)2(P-Me2Ph)2,265 cis- and zra s-Os(S2COMe)2(PPh3)2,266 Co(S2 COMe)3.267... 

The first report on the anticancer properties of ruthenium was published in 1976 when the Ru(III) compound /ac-[RuC13(NH3)3] (Fig. 11) was found to induce filamentous growth of Escherichia coli at concentrations comparable to those at which cisplatin generates similar effects (49). This Ru(III) complex and related compounds such as cis-[RuCl2(NH3)4]Cl illustrated the potential anticancer activity of ruthenium complexes, but insolubility prevented further pharmacological use. Since these initial studies, other Ru(III) complexes have been studied for potential anticancer activity, and two compounds, NAMI-A (50) and KP1019 (51), are currently undergoing clinical trials. Remarkably,... 

---